2021
Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study
Cox H, Salaam-Dreyer Z, Goig GA, Nicol MP, Menardo F, Dippenaar A, Mohr-Holland E, Daniels J, Cudahy PGT, Borrell S, Reinhard M, Doetsch A, Beisel C, Reuter A, Furin J, Gagneux S, Warren RM. Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study. The Lancet Microbe 2021, 2: e584-e593. PMID: 34766068, PMCID: PMC8563432, DOI: 10.1016/s2666-5247(21)00144-0.Peer-Reviewed Original ResearchConceptsFirst-line tuberculosis treatmentPrevious tuberculosis treatmentRifampicin-resistant tuberculosisRifampicin-monoresistant tuberculosisTuberculosis treatmentHIV positivityCohort studyLarge-scale prospective cohort studyResistance acquisitionPrevious treatmentRetrospective cohort studyProspective cohort studyTuberculosis drug resistancePatient-level dataLogistic regression analysisWhole-genome sequencingMolecular epidemiology studiesProspective databaseMDR tuberculosisRetrospective cohortFemale sexHigh burdenPatientsHIVEpidemiology studies
2017
Improved Survival and Cure Rates With Concurrent Treatment for Multidrug-Resistant Tuberculosis–Human Immunodeficiency Virus Coinfection in South Africa
Brust JCM, Shah NS, Mlisana K, Moodley P, Allana S, Campbell A, Johnson BA, Master I, Mthiyane T, Lachman S, Larkan LM, Ning Y, Malik A, Smith JP, Gandhi NR. Improved Survival and Cure Rates With Concurrent Treatment for Multidrug-Resistant Tuberculosis–Human Immunodeficiency Virus Coinfection in South Africa. Clinical Infectious Diseases 2017, 66: 1246-1253. PMID: 29293906, PMCID: PMC5888963, DOI: 10.1093/cid/cix1125.Peer-Reviewed Original ResearchConceptsCells/mm3Immunodeficiency virus coinfectionAntiretroviral therapyMDR tuberculosisCD4 countVirus coinfectionConcurrent treatmentTreatment outcomesHuman immunodeficiency virus (HIV) coinfectionUndetectable HIV viral loadConcurrent antiretroviral therapyMDR tuberculosis patientsHIV viral loadMultidrug-resistant tuberculosisStrong risk factorTuberculosis-HIVTuberculosis outcomesAdverse eventsTuberculosis patientsImproved survivalMedian agePrimary outcomeHIV statusViral loadCure rate
2015
Identifying Hotspots of Multidrug-Resistant Tuberculosis Transmission Using Spatial and Molecular Genetic Data
Zelner JL, Murray MB, Becerra MC, Galea J, Lecca L, Calderon R, Yataco R, Contreras C, Zhang Z, Manjourides J, Grenfell BT, Cohen T. Identifying Hotspots of Multidrug-Resistant Tuberculosis Transmission Using Spatial and Molecular Genetic Data. The Journal Of Infectious Diseases 2015, 213: 287-294. PMID: 26175455, PMCID: PMC4690150, DOI: 10.1093/infdis/jiv387.Peer-Reviewed Original ResearchConceptsMDR tuberculosisDrug susceptibilityTuberculosis casesMultidrug-resistant tuberculosis (MDR-TB) transmissionCulture-confirmed diseaseHealth Center areaProspective cohort studyCapita incidenceHousehold contactsCohort studyTuberculosis riskTuberculosis transmissionSymptomatic individualsHigh riskPositive culturesNumber tandem repeatRiskEtiology
2009
Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis
Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. The Lancet Infectious Diseases 2009, 9: 153-161. PMID: 19246019, DOI: 10.1016/s1473-3099(09)70041-6.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisTreatment outcomesHIV statusTreatment regimensStrong patient supportProportion of patientsPatient's HIV statusTuberculosis treatment programmesHigher treatment successSuccessful treatment outcomePublic health concernStandardised regimensMDR tuberculosisObserved therapyPatient populationTreatment completionTreatment successInclusion criteriaPatient supportTherapeutic studiesClinical reportsTreatment approachesTreatment durationPatientsSystematic review
2006
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa
Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. The Lancet 2006, 368: 1575-1580. PMID: 17084757, DOI: 10.1016/s0140-6736(06)69573-1.Peer-Reviewed Original ResearchConceptsDrug-resistant tuberculosisCo-infected patientsXDR tuberculosisMDR tuberculosisHIV co-infected patientsCulture-confirmed tuberculosisRecent hospital admissionTime of diagnosisSecond-line drugsDrug susceptibility testingCause of deathDate of deathHigh mortality rateAntiretroviral therapyMedian survivalHospital admissionSputum cultureHIV-1PatientsMortality rateHigh mortalityUrgent interventionTreatment programTuberculosisSusceptibility testing
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply